Kinga Szigeti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kinga Szigeti has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Ivanna Ihnatovych
Department of Neurology, State University of New York at Buffalo, 875 Ellicott St, Buffalo, NY, 14203, USA
8 shared publicationsLi Yan
Roswell Park Comprehensive Cancer Center, University at Buffalo, SUNY, Buffalo, NY
5 shared publicationsNorbert Sule
Roswell Park Comprehensive Cancer Center
5 shared publicationsMatthew R. Woodward
Alzheimer's Disease and Memory Disorders Center, Department of Neurology, University at Buffalo, SUNY, Buffalo, NY
4 shared publicationsRalph H.B. Benedict
State University of New York at Buffalo, 875 Ellicott St., Buffalo, NY, 14203, USA
4 shared publicationsRyu P. Dorn
Department of Neurology, State University of New York at Buffalo
4 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Springer Nature in BMC Neuroscience
Proteomic profiling reveals structural and adhesion pathways regulated by the inverted CHRFAM7AΔ2bp variant in human neural progenitor cells
The CHRNA7 gene, located on chromosome 15q13.3, encodes the α7 nicotinic acetylcholine receptor (α7 nAChR) subunit and lies within a genomic region characterized by high recombination rates and associations with multiple neuropsychiatric disorders. Within this region, the human specific gene CHRFAM7A arose through partial duplication, rearrangement, and fusion between CHRNA7 and FAM7A. The direct CHRFAM7A allele has been shown to negatively regulate α7 nAChR function. The inverted allele (CHRFAM7AΔ2bp), harboring a two-base pair deletion in exon 6, is linked to schizophrenia, bipolar disorder, and other psychiatric conditions. In this study, we investigated how the presence of the CHRFAM7AΔ2bp allele alters the cellular proteome. Using high-throughput proteomic analysis by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS), we characterized protein expression in neuronal progenitors differentiated from isogenic human induced pluripotent stem cell (iPSC) lines representing CHRFAM7AΔ2bp and CHRFAM7A-null genotypes. Comparative analysis identified 129 differentially expressed proteins enriched in pathways related to extracellular matrix organization, collagen biosynthesis, and cell adhesion. Functional assays further demonstrated differences in matrix adhesion between CHRFAM7A-null and CHRFAM7AΔ2bp-derived progenitors. These results suggest that the CHRFAM7AΔ2bp variant influences cellular structure through modulation of adhesion matrix-interaction proteins. This work provides insight into molecular mechanisms that may underlie increased neurodisease vulnerability associated with this genotype.
- 13 June 2026
- Published by Springer Nature in BMC Neuroscience
Open AccessProteomic profiling reveals structural and adhesion pathways regulated by the inverted CHRFAM7AΔ2bp variant in human neural progenitor cells
The CHRNA7 gene, located on chromosome 15q13.3, encodes the α7 nicotinic acetylcholine receptor (α7 nAChR) subunit and lies within a genomic region characterized by high recombination rates and associations with multiple neuropsychiatric disorders. Within this region, the human specific gene CHRFAM7A arose through partial duplication, rearrangement, and fusion between CHRNA7 and FAM7A. The direct CHRFAM7A allele has been shown to negatively regulate α7 nAChR function. The inverted allele (CHRFAM7AΔ2bp), harboring a two-base pair deletion in exon 6, is linked to schizophrenia, bipolar disorder, and other psychiatric conditions. In this study, we investigated how the presence of the CHRFAM7AΔ2bp allele alters the cellular proteome. Using high-throughput proteomic analysis by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS), we characterized protein expression in neuronal progenitors differentiated from isogenic human induced pluripotent stem cell (iPSC) lines representing CHRFAM7AΔ2bp and CHRFAM7A-null genotypes. Comparative analysis identified 129 differentially expressed proteins enriched in pathways related to extracellular matrix organization, collagen biosynthesis, and cell adhesion. Functional assays further demonstrated differences in matrix adhesion between CHRFAM7A-null and CHRFAM7AΔ2bp-derived progenitors. These results suggest that the CHRFAM7AΔ2bp variant influences cellular structure through modulation of adhesion matrix-interaction proteins. This work provides insight into molecular mechanisms that may underlie increased neurodisease vulnerability associated with this genotype.
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1786287
The effect of human-specific genetic variants on neuronal spinogenesis
Fundamental morphological and functional differences between the brains of animal models and humans are at least partially related to human-specific genes and genetic variants. As one of the structural underpinnings of brain function is the dendritic spine, we systematically queried a curated list of human-specific genes and genetic variants. We found that with the current knowledge base, 4.3% are linked to the dendritic spine. Functionally these genes converge on the cytoskeleton, Ca 2+ signaling, small GTPases, NMDAR, and WNT signaling and trafficking suggesting human specific modification of canonical pathways. Significant gaps in knowledge are identified and concerted efforts are needed. Understanding human-specific genetic contributions to the unique features of the human brain will address existing translational gaps and facilitate the development of successful treatments for neuropsychiatric disorders, advance environmental neuroscience for early childhood intervention and environmental risk reduction in aging and dementia.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1786287
Open AccessThe effect of human-specific genetic variants on neuronal spinogenesis
Fundamental morphological and functional differences between the brains of animal models and humans are at least partially related to human-specific genes and genetic variants. As one of the structural underpinnings of brain function is the dendritic spine, we systematically queried a curated list of human-specific genes and genetic variants. We found that with the current knowledge base, 4.3% are linked to the dendritic spine. Functionally these genes converge on the cytoskeleton, Ca 2+ signaling, small GTPases, NMDAR, and WNT signaling and trafficking suggesting human specific modification of canonical pathways. Significant gaps in knowledge are identified and concerted efforts are needed. Understanding human-specific genetic contributions to the unique features of the human brain will address existing translational gaps and facilitate the development of successful treatments for neuropsychiatric disorders, advance environmental neuroscience for early childhood intervention and environmental risk reduction in aging and dementia.
- Open Access
Binary partitioning of human brain organization due to divergent human cytoskeletal evolution
CHRFAM7A is a biallelic uniquely human fusion gene present in 99.3% of humans. The direct and inverted alleles likely emerged independently in Africa and East Asia. We uncovered that the inverted allele regulates ULK4 expression through genetic epistasis. The increase in long to short ULK4 isoform ratio enhances a-tubulin acetylation leading to microtubule (MT) cytoskeleton phenotypes (cell body: microtubule rich projections; neurite: de-bundling; growth cone: fanning with MT invasion). The MT cytoskeleton gain of function enhances neuronal arborization and functional connectivity in the human brain. Considering that the previously reported direct allele leads to actin cytoskeleton gain of function, we propose that CHRFAM7A alleles represent binary human genetic background through divergent evolution of the cytoskeleton. In the human brain the two alleles represent distinct brain organization: the direct allele enhances microstructure as measured by diffusion tensor imaging while the inverted allele increases functional connectivity with increased small world propensity. The two types of brain organization likely represent different susceptibility to neuropsychiatric disease and may underlie the allelic disease associations.
Open AccessBinary partitioning of human brain organization due to divergent human cytoskeletal evolution
CHRFAM7A is a biallelic uniquely human fusion gene present in 99.3% of humans. The direct and inverted alleles likely emerged independently in Africa and East Asia. We uncovered that the inverted allele regulates ULK4 expression through genetic epistasis. The increase in long to short ULK4 isoform ratio enhances a-tubulin acetylation leading to microtubule (MT) cytoskeleton phenotypes (cell body: microtubule rich projections; neurite: de-bundling; growth cone: fanning with MT invasion). The MT cytoskeleton gain of function enhances neuronal arborization and functional connectivity in the human brain. Considering that the previously reported direct allele leads to actin cytoskeleton gain of function, we propose that CHRFAM7A alleles represent binary human genetic background through divergent evolution of the cytoskeleton. In the human brain the two alleles represent distinct brain organization: the direct allele enhances microstructure as measured by diffusion tensor imaging while the inverted allele increases functional connectivity with increased small world propensity. The two types of brain organization likely represent different susceptibility to neuropsychiatric disease and may underlie the allelic disease associations.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e098688
Human specific divergent cytoskeletal evolution defines genetic background for innate immune function
Background: Innate immune response is dependent on the ability of monocytes to infiltrate the tissue niches where pathogens reside, or tissue damage occurs. CHRFAM7A is a bi‐allelic uniquely human fusion gene between CHRNA7 and ULK4 present in 99.3% of humans. α7 nAChR has been implicated in innate immunity and as part of the cholinergic anti‐inflammatory response. The effect of CHRFAM7A alleles on innate immune function is unknown. Method: Isogenic iPSC derived microglia and monocytes are utilized as a model system and validated in human primary monocytes (N=100 donors). Actin and tubulin live imaging, migration and invasion assays are used to functionally characterize the alleles. Adaptive function to the mechanical properties of the tissue environment are studied on hydrogel models. Result: The translated direct allele leads to a hypomorphic α7 nicotinic acetylcholine receptor, while the inverted structural variant (SV) allele skews ULK4 short and long isoform ratio through genetic epistasis. The direct allele activates Rac1 and leads to a dynamic actin cytoskeleton and phenotypic switch to lamellipodia while the inverted allele acetylates a‐tubulin and stabilizes the microtubule cytoskeleton. Consequently, the alleles use distinct mechanisms for locomotion (direct‐invasion and inverted‐migration) and adaptation to hydrogel stiffness (direct‐lamellipodia and inverted‐polarization). Conclusion: CHRFAM7A infers divergent cytoskeletal gain of function leading to adaptation to tissue stiffness and chemotaxis. Importantly, the mechanism is not only human specific, but has a dichotomy with equal allele frequencies of the two CHRFAM7A alleles (direct and inverted) suggesting potentially profound translational significance. Understanding this bi‐allelic human genetic background builds the foundation for targeted therapeutic intervention for neuroinflammation.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S5) , e098688
Open AccessHuman specific divergent cytoskeletal evolution defines genetic background for innate immune function
Background: Innate immune response is dependent on the ability of monocytes to infiltrate the tissue niches where pathogens reside, or tissue damage occurs. CHRFAM7A is a bi‐allelic uniquely human fusion gene between CHRNA7 and ULK4 present in 99.3% of humans. α7 nAChR has been implicated in innate immunity and as part of the cholinergic anti‐inflammatory response. The effect of CHRFAM7A alleles on innate immune function is unknown. Method: Isogenic iPSC derived microglia and monocytes are utilized as a model system and validated in human primary monocytes (N=100 donors). Actin and tubulin live imaging, migration and invasion assays are used to functionally characterize the alleles. Adaptive function to the mechanical properties of the tissue environment are studied on hydrogel models. Result: The translated direct allele leads to a hypomorphic α7 nicotinic acetylcholine receptor, while the inverted structural variant (SV) allele skews ULK4 short and long isoform ratio through genetic epistasis. The direct allele activates Rac1 and leads to a dynamic actin cytoskeleton and phenotypic switch to lamellipodia while the inverted allele acetylates a‐tubulin and stabilizes the microtubule cytoskeleton. Consequently, the alleles use distinct mechanisms for locomotion (direct‐invasion and inverted‐migration) and adaptation to hydrogel stiffness (direct‐lamellipodia and inverted‐polarization). Conclusion: CHRFAM7A infers divergent cytoskeletal gain of function leading to adaptation to tissue stiffness and chemotaxis. Importantly, the mechanism is not only human specific, but has a dichotomy with equal allele frequencies of the two CHRFAM7A alleles (direct and inverted) suggesting potentially profound translational significance. Understanding this bi‐allelic human genetic background builds the foundation for targeted therapeutic intervention for neuroinflammation.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S6)
Human restricted CHRFAM7A mediates neuronal and innate immune gain of function
Background: Understanding the fundamental differences between the human and pre‐human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP). The emerging pathways are tested and validated in an isogenic hiPSC model of CHRFAM7A knock‐in neurons and monocytes. In vivo validation is performed in a double blind pharmacogenetic study on the effect of nicotinic acetyl‐choline esterase inhibitor therapy. The effect of CHRFAM7A carrier status was assessed in two paradigms: response to drug initiation and disease modifying therapy (DMT) effect over an 8 year observation period. Fitted general linear model independent variables included age, sex, and medication regimen at the time of the first MMSE, APOE4 carrier status (0, 1 or 2 alleles as categorical variables) and CHRFAM7A genotype.Result: CHRFAM7A is identified as a modulator of intracellular calcium dynamics and an upstream regulator of Rac1. Rac1 activation re‐designs the actin cytoskeleton leading to dynamic actin driven remodeling of membrane protrusion and a switch from filopodia to lamellipodia. Phenotypic readouts in both the neuronal and monocytic lineages confirm actin cytoskeleton gain of function. The actin cytoskeleton reorganization shifts dendritic spine differentiation from filopodia towards spines with increased head area to stem diameter ratio resulting in increased synapse clustering (“high quality wellcro”) in neurons. In monocytes, the reorganized actin cytoskeleton leads to increased invasion, phagocytosis and cytokine release. These data suggest a shift from neurodegenerative to neuroinflammatory mechanism in 75% of AD patients. From the cholinergic treatment perspective incorporation into the a7 nAChR pentamer results in a hypomorphic receptor, which has diminished response to pharmacological modulation. Proof of principle pharmacogenetic study found a CHRFAM7A effect on treatment response both in the acute response and DMT paradigms.Conclusion: Human restricted CHRFAM7A defines the biological background for AD pathology by shifting neurodegeneration to neuroinflammation in a 25‐75% split. Introducing a CHRFAM7A model into the target selection workflow may increase clinical trial success.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S6)
Open AccessHuman restricted CHRFAM7A mediates neuronal and innate immune gain of function
Background: Understanding the fundamental differences between the human and pre‐human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP). The emerging pathways are tested and validated in an isogenic hiPSC model of CHRFAM7A knock‐in neurons and monocytes. In vivo validation is performed in a double blind pharmacogenetic study on the effect of nicotinic acetyl‐choline esterase inhibitor therapy. The effect of CHRFAM7A carrier status was assessed in two paradigms: response to drug initiation and disease modifying therapy (DMT) effect over an 8 year observation period. Fitted general linear model independent variables included age, sex, and medication regimen at the time of the first MMSE, APOE4 carrier status (0, 1 or 2 alleles as categorical variables) and CHRFAM7A genotype.Result: CHRFAM7A is identified as a modulator of intracellular calcium dynamics and an upstream regulator of Rac1. Rac1 activation re‐designs the actin cytoskeleton leading to dynamic actin driven remodeling of membrane protrusion and a switch from filopodia to lamellipodia. Phenotypic readouts in both the neuronal and monocytic lineages confirm actin cytoskeleton gain of function. The actin cytoskeleton reorganization shifts dendritic spine differentiation from filopodia towards spines with increased head area to stem diameter ratio resulting in increased synapse clustering (“high quality wellcro”) in neurons. In monocytes, the reorganized actin cytoskeleton leads to increased invasion, phagocytosis and cytokine release. These data suggest a shift from neurodegenerative to neuroinflammatory mechanism in 75% of AD patients. From the cholinergic treatment perspective incorporation into the a7 nAChR pentamer results in a hypomorphic receptor, which has diminished response to pharmacological modulation. Proof of principle pharmacogenetic study found a CHRFAM7A effect on treatment response both in the acute response and DMT paradigms.Conclusion: Human restricted CHRFAM7A defines the biological background for AD pathology by shifting neurodegeneration to neuroinflammation in a 25‐75% split. Introducing a CHRFAM7A model into the target selection workflow may increase clinical trial success.
- Open Access
- 22 April 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1359028
Human restricted CHRFAM7A gene increases brain efficiency
Introduction: CHRFAM7A, a uniquely human fusion gene, has been associated with neuropsychiatric disorders including Alzheimer’s disease, schizophrenia, anxiety, and attention deficit disorder. Understanding the physiological function of CHRFAM7A in the human brain is the first step to uncovering its role in disease. CHRFAM7A was identified as a potent modulator of intracellular calcium and an upstream regulator of Rac1 leading to actin cytoskeleton reorganization and a switch from filopodia to lamellipodia implicating a more efficient neuronal structure. We performed a neurocognitive-MRI correlation exploratory study on 46 normal human subjects to explore the effect of CHRFAM7A on human brain.Methods: Dual locus specific genotyping of CHRFAM7A was performed on genomic DNA to determine copy number (TaqMan assay) and orientation (capillary sequencing) of the CHRFAM7A alleles. As only the direct allele is expressed at the protein level and affects α7 nAChR function, direct allele carriers and non-carriers are compared for neuropsychological and MRI measures. Subjects underwent neuropsychological testing to measure motor (Timed 25-foot walk test, 9-hole peg test), cognitive processing speed (Symbol Digit Modalities Test), Learning and memory (California Verbal Learning Test immediate and delayed recall, Brief Visuospatial Memory Test—Revised immediate and delayed recall) and Beck Depression Inventory—Fast Screen, Fatigue Severity Scale. All subjects underwent MRI scanning on the same 3 T GE scanner using the same protocol. Global and tissue-specific volumes were determined using validated cross-sectional algorithms including FSL’s Structural Image Evaluation, using Normalization, of Atrophy (SIENAX) and FSL’s Integrated Registration and Segmentation Tool (FIRST) on lesion-inpainted images. The cognitive tests were age and years of education-adjusted using analysis of covariance (ANCOVA). Age-adjusted analysis of covariance (ANCOVA) was performed on the MRI data.Results: CHRFAM7A direct allele carrier and non-carrier groups included 33 and 13 individuals, respectively. Demographic variables (age and years of education) were comparable. CHRFAM7A direct allele carriers demonstrated an upward shift in cognitive performance including cognitive processing speed, learning and memory, reaching statistical significance in visual immediate recall (FDR corrected p = 0.018). The shift in cognitive performance was associated with smaller whole brain volume (uncorrected p = 0.046) and lower connectivity by resting state functional MRI in the visual network (FDR corrected p = 0.027) accentuating the cognitive findings.Conclusion: These data suggest that direct allele carriers harbor a more efficient brain consistent with the cellular biology of actin cytoskeleton and synaptic gain of function. Further larger human studies of cognitive measures correlated with MRI and functional imaging are needed to decipher the impact of CHRFAM7A on brain function.
- 22 April 2024
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 18, 1359028
Open AccessHuman restricted CHRFAM7A gene increases brain efficiency
Introduction: CHRFAM7A, a uniquely human fusion gene, has been associated with neuropsychiatric disorders including Alzheimer’s disease, schizophrenia, anxiety, and attention deficit disorder. Understanding the physiological function of CHRFAM7A in the human brain is the first step to uncovering its role in disease. CHRFAM7A was identified as a potent modulator of intracellular calcium and an upstream regulator of Rac1 leading to actin cytoskeleton reorganization and a switch from filopodia to lamellipodia implicating a more efficient neuronal structure. We performed a neurocognitive-MRI correlation exploratory study on 46 normal human subjects to explore the effect of CHRFAM7A on human brain.Methods: Dual locus specific genotyping of CHRFAM7A was performed on genomic DNA to determine copy number (TaqMan assay) and orientation (capillary sequencing) of the CHRFAM7A alleles. As only the direct allele is expressed at the protein level and affects α7 nAChR function, direct allele carriers and non-carriers are compared for neuropsychological and MRI measures. Subjects underwent neuropsychological testing to measure motor (Timed 25-foot walk test, 9-hole peg test), cognitive processing speed (Symbol Digit Modalities Test), Learning and memory (California Verbal Learning Test immediate and delayed recall, Brief Visuospatial Memory Test—Revised immediate and delayed recall) and Beck Depression Inventory—Fast Screen, Fatigue Severity Scale. All subjects underwent MRI scanning on the same 3 T GE scanner using the same protocol. Global and tissue-specific volumes were determined using validated cross-sectional algorithms including FSL’s Structural Image Evaluation, using Normalization, of Atrophy (SIENAX) and FSL’s Integrated Registration and Segmentation Tool (FIRST) on lesion-inpainted images. The cognitive tests were age and years of education-adjusted using analysis of covariance (ANCOVA). Age-adjusted analysis of covariance (ANCOVA) was performed on the MRI data.Results: CHRFAM7A direct allele carrier and non-carrier groups included 33 and 13 individuals, respectively. Demographic variables (age and years of education) were comparable. CHRFAM7A direct allele carriers demonstrated an upward shift in cognitive performance including cognitive processing speed, learning and memory, reaching statistical significance in visual immediate recall (FDR corrected p = 0.018). The shift in cognitive performance was associated with smaller whole brain volume (uncorrected p = 0.046) and lower connectivity by resting state functional MRI in the visual network (FDR corrected p = 0.027) accentuating the cognitive findings.Conclusion: These data suggest that direct allele carriers harbor a more efficient brain consistent with the cellular biology of actin cytoskeleton and synaptic gain of function. Further larger human studies of cognitive measures correlated with MRI and functional imaging are needed to decipher the impact of CHRFAM7A on brain function.
- Open Access
- 2 April 2024
- Published by Elsevier in EBioMedicine
- Vol. 103, 105093
CHRFAM7A diversifies human immune adaption through Ca2+ signalling and actin cytoskeleton reorganization
- 2 April 2024
- Published by Elsevier in EBioMedicine
- Vol. 103, 105093
Open AccessCHRFAM7A diversifies human immune adaption through Ca2+ signalling and actin cytoskeleton reorganization
- Open Access
- 10 January 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (4) , 1020-1032
Translational implications of CHRFAM7A, an elusive human-restricted fusion gene
Genes restricted to humans may contribute to human-specific traits and provide a different context for diseases.CHRFAM7Ais a uniquely human fusion gene and a negative regulator of the α7 nicotinic acetylcholine receptor (α7 nAChR). The α7 nAChR has been a promising target for diseases affecting cognition and higher cortical functions, however, the treatment effect observed in animal models failed to translate into human clinical trials. AsCHRFAM7Awas not accounted for in preclinical drug screens it may have contributed to the translational gap. Understanding the complex genetic architecture of the locus, deciphering the functional impact of CHRFAM7A on α7 nAChR neurobiology and utilizing human-relevant models may offer novel approaches to explore α7 nAChR as a drug target.
- 10 January 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (4) , 1020-1032
Open AccessTranslational implications of CHRFAM7A, an elusive human-restricted fusion gene
Genes restricted to humans may contribute to human-specific traits and provide a different context for diseases.CHRFAM7Ais a uniquely human fusion gene and a negative regulator of the α7 nicotinic acetylcholine receptor (α7 nAChR). The α7 nAChR has been a promising target for diseases affecting cognition and higher cortical functions, however, the treatment effect observed in animal models failed to translate into human clinical trials. AsCHRFAM7Awas not accounted for in preclinical drug screens it may have contributed to the translational gap. Understanding the complex genetic architecture of the locus, deciphering the functional impact of CHRFAM7A on α7 nAChR neurobiology and utilizing human-relevant models may offer novel approaches to explore α7 nAChR as a drug target.
- Open Access
- 28 July 2023
- Published by Elsevier in EBioMedicine
- Vol. 95, 104725
Neuronal actin cytoskeleton gain of function in the human brain
- 28 July 2023
- Published by Elsevier in EBioMedicine
- Vol. 95, 104725
Open AccessNeuronal actin cytoskeleton gain of function in the human brain
- 30 March 2022
- Published by Springer Nature in CNS Drugs
- Vol. 36 (4) , 365-376
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease
The development of Alzheimer’s disease therapeutics has been challenging, with 99% of clinical trials failing to find a significant difference between drug and placebo. While the quest continues for more effective treatments, there is emerging evidence that pharmacogenetic considerations are important factors in regard to metabolism, efficacy, and toxicity of drugs. Currently, there are five US Food and Drug Administration-approved drugs for the treatment of Alzheimer’s disease; three acetylcholinesterase inhibitors, memantine, and aducanumab. Introducing a limited genetic panel consisting of APOE4, CYP2D6*10, and BChE*K would optimize acetylcholinesterase inhibitor therapy, facilitate immunotherapy risk assessment, and inform an amyloid-related imaging abnormality surveillance schedule. In view of the genetic heterogeneity of Alzheimer’s disease identified in genome-wide association studies, pharmacogenetics is expected to play an increasing role in mechanism-specific treatment strategies and personalized medicine.
- 30 March 2022
- Published by Springer Nature in CNS Drugs
- Vol. 36 (4) , 365-376
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease
The development of Alzheimer’s disease therapeutics has been challenging, with 99% of clinical trials failing to find a significant difference between drug and placebo. While the quest continues for more effective treatments, there is emerging evidence that pharmacogenetic considerations are important factors in regard to metabolism, efficacy, and toxicity of drugs. Currently, there are five US Food and Drug Administration-approved drugs for the treatment of Alzheimer’s disease; three acetylcholinesterase inhibitors, memantine, and aducanumab. Introducing a limited genetic panel consisting of APOE4, CYP2D6*10, and BChE*K would optimize acetylcholinesterase inhibitor therapy, facilitate immunotherapy risk assessment, and inform an amyloid-related imaging abnormality surveillance schedule. In view of the genetic heterogeneity of Alzheimer’s disease identified in genome-wide association studies, pharmacogenetics is expected to play an increasing role in mechanism-specific treatment strategies and personalized medicine.